ID   TAOK2_HUMAN             Reviewed;        1235 AA.
AC   Q9UL54; A5PKY1; A7MCZ2; B2RN35; B7ZM88; O94957; Q6UW73; Q7LC09;
AC   Q9NSW2;
DT   25-OCT-2005, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   15-MAR-2017, entry version 150.
DE   RecName: Full=Serine/threonine-protein kinase TAO2;
DE            EC=2.7.11.1;
DE   AltName: Full=Kinase from chicken homolog C;
DE            Short=hKFC-C;
DE   AltName: Full=Prostate-derived sterile 20-like kinase 1;
DE            Short=PSK-1;
DE            Short=PSK1;
DE            Short=Prostate-derived STE20-like kinase 1;
DE   AltName: Full=Thousand and one amino acid protein kinase 2;
GN   Name=TAOK2; Synonyms=KIAA0881, MAP3K17, PSK, PSK1;
GN   ORFNames=UNQ2971/PRO7431;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   AND MUTAGENESIS OF LYS-57.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=10660600; DOI=10.1074/jbc.275.6.4311;
RA   Moore T.M., Garg R., Johnson C., Coptcoat M.J., Ridley A.J.,
RA   Morris J.D.H.;
RT   "PSK, a novel STE20-like kinase derived from prostatic carcinoma that
RT   activates the JNK MAPK pathway and regulates actin cytoskeletal
RT   organisation.";
RL   J. Biol. Chem. 275:4311-4322(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, SELF-ASSOCIATION,
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=13679851; DOI=10.1038/sj.onc.1206605;
RA   Yustein J.T., Xia L., Kahlenburg J.M., Robinson D., Templeton D.,
RA   Kung H.-J.;
RT   "Comparative studies of a new subfamily of human Ste20-like kinases:
RT   homodimerization, subcellular localization, and selective activation
RT   of MKK3 and p38.";
RL   Oncogene 22:6129-6141(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=10048485; DOI=10.1093/dnares/5.6.355;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M.,
RA   Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XII.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 5:355-364(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Fetal brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 4).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 957-1235 (ISOFORMS 1/3).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF MAP2K3 AND MAP2K6, AND INTERACTION WITH
RP   MAP2K3 AND MAP2K6.
RX   PubMed=11279118; DOI=10.1074/jbc.M100681200;
RA   Chen Z., Cobb M.H.;
RT   "Regulation of stress-responsive mitogen-activated protein (MAP)
RT   kinase pathways by TAO2.";
RL   J. Biol. Chem. 276:16070-16075(2001).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH TUBULINS, AND
RP   MUTAGENESIS OF LYS-57.
RX   PubMed=12639963; DOI=10.1074/jbc.M213064200;
RA   Mitsopoulos C., Zihni C., Garg R., Ridley A.J., Morris J.D.;
RT   "The prostate-derived sterile 20-like kinase (PSK) regulates
RT   microtubule organization and stability.";
RL   J. Biol. Chem. 278:18085-18091(2003).
RN   [12]
RP   FUNCTION.
RX   PubMed=12665513; DOI=10.1074/jbc.M301173200;
RA   Chen Z., Raman M., Chen L., Lee S.F., Gilman A.G., Cobb M.H.;
RT   "TAO (thousand-and-one amino acid) protein kinases mediate signaling
RT   from carbachol to p38 mitogen-activated protein kinase and ternary
RT   complex factors.";
RL   J. Biol. Chem. 278:22278-22283(2003).
RN   [13]
RP   FUNCTION, INTERACTION WITH MAP3K7, AND MUTAGENESIS OF LYS-57 AND
RP   ASP-169.
RX   PubMed=16893890; DOI=10.1074/jbc.M603627200;
RA   Huangfu W.C., Omori E., Akira S., Matsumoto K., Ninomiya-Tsuji J.;
RT   "Osmotic stress activates the TAK1-JNK pathway while blocking TAK1-
RT   mediated NF-kappaB activation: TAO2 regulates TAK1 pathways.";
RL   J. Biol. Chem. 281:28802-28810(2006).
RN   [14]
RP   FUNCTION, PHOSPHORYLATION BY ATM, AND INDUCTION.
RX   PubMed=17396146; DOI=10.1038/sj.emboj.7601668;
RA   Raman M., Earnest S., Zhang K., Zhao Y., Cobb M.H.;
RT   "TAO kinases mediate activation of p38 in response to DNA damage.";
RL   EMBO J. 26:2005-2014(2007).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-181,
RP   AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LYS-57 AND ASP-919.
RX   PubMed=17158878; DOI=10.1074/jbc.M608336200;
RA   Zihni C., Mitsopoulos C., Tavares I.A., Baum B., Ridley A.J.,
RA   Morris J.D.;
RT   "Prostate-derived sterile 20-like kinase 1-alpha induces apoptosis.
RT   JNK-and caspase-dependent nuclear localization is a requirement for
RT   membrane blebbing.";
RL   J. Biol. Chem. 282:6484-6493(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9 AND SER-777, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [17]
RP   ENZYME REGULATION.
RX   PubMed=19226137; DOI=10.1021/jm8005806;
RA   Anand R., Maksimoska J., Pagano N., Wong E.Y., Gimotty P.A.,
RA   Diamond S.L., Meggers E., Marmorstein R.;
RT   "Toward the development of a potent and selective organoruthenium
RT   mammalian sterile 20 kinase inhibitor.";
RL   J. Med. Chem. 52:1602-1611(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9 AND SER-181,
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1011 (ISOFORM 2), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [19]
RP   ENZYME REGULATION.
RX   PubMed=20159944; DOI=10.1124/mol.109.061507;
RA   McNeer J.L., Goussetis D.J., Sassano A., Dolniak B., Kroczynska B.,
RA   Glaser H., Altman J.K., Platanias L.C.;
RT   "Arsenic trioxide-dependent activation of thousand-and-one amino acid
RT   kinase 2 and transforming growth factor-beta-activated kinase 1.";
RL   Mol. Pharmacol. 77:828-835(2010).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-825 AND SER-827, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9 AND SER-827, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-414, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Serine/threonine-protein kinase involved in different
CC       processes such as membrane blebbing and apoptotic bodies formation
CC       DNA damage response and MAPK14/p38 MAPK stress-activated MAPK
CC       cascade. Phosphorylates itself, MBP, activated MAPK8, MAP2K3,
CC       MAP2K6 and tubulins. Activates the MAPK14/p38 MAPK signaling
CC       pathway through the specific activation and phosphorylation of the
CC       upstream MAP2K3 and MAP2K6 kinases. In response to DNA damage,
CC       involved in the G2/M transition DNA damage checkpoint by
CC       activating the p38/MAPK14 stress-activated MAPK cascade, probably
CC       by mediating phosphorylation of upstream MAP2K3 and MAP2K6
CC       kinases. Isoform 1, but not isoform 2, plays a role in apoptotic
CC       morphological changes, including cell contraction, membrane
CC       blebbing and apoptotic bodies formation. This function, which
CC       requires the activation of MAPK8/JNK and nuclear localization of
CC       C-terminally truncated isoform 1, may be linked to the
CC       mitochondrial CASP9-associated death pathway. Isoform 1 binds to
CC       microtubules and affects their organization and stability
CC       independently of its kinase activity. Prevents MAP3K7-mediated
CC       activation of CHUK, and thus NF-kappa-B activation, but not that
CC       of MAPK8/JNK. May play a role in the osmotic stress-MAPK8 pathway.
CC       Isoform 2, but not isoform 1, is required for PCDH8 endocytosis.
CC       Following homophilic interactions between PCDH8 extracellular
CC       domains, isoform 2 phosphorylates and activates MAPK14/p38 MAPK
CC       which in turn phosphorylates isoform 2. This process leads to
CC       PCDH8 endocytosis and CDH2 cointernalization. Both isoforms are
CC       involved in MAPK14 phosphorylation. {ECO:0000269|PubMed:10660600,
CC       ECO:0000269|PubMed:11279118, ECO:0000269|PubMed:12639963,
CC       ECO:0000269|PubMed:12665513, ECO:0000269|PubMed:13679851,
CC       ECO:0000269|PubMed:16893890, ECO:0000269|PubMed:17158878,
CC       ECO:0000269|PubMed:17396146}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Selectively inhibited by the enantiopure
CC       organoruthenium inhibitor 9E1. Activated following arsenic
CC       trioxide (As(2)O(3)) treatment. {ECO:0000269|PubMed:19226137,
CC       ECO:0000269|PubMed:20159944}.
CC   -!- SUBUNIT: Interacts with MAP2K3 and MAP2K6 (By similarity). Self-
CC       associates. Interacts with tubulins through the C-terminal domain.
CC       Interacts with MAP3K7 and interfers with MAP3K7-binding to CHUK
CC       and thus prevents NF-kappa-B activation. Isoform 2 interacts with
CC       PCDH8; this complex may also include CDH2 (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle membrane {ECO:0000305};
CC       Multi-pass membrane protein {ECO:0000305}. Cytoplasm,
CC       cytoskeleton. Nucleus. Note=Catalytically active full-length
CC       phosphorylated isoform 1 localizes to microtubules in the
CC       cytoplasm predominantly on microtubule cables positioned around
CC       the nucleus. A C-terminally truncated form of isoform 1 is present
CC       in the nucleus; isoform 2 and kinase-defective, as well as full-
CC       length isoform 1 are excluded from the nucleus.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell projection, dendrite.
CC       Note=In dendrites, colocalizes with PCDH8. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=PSK1-alpha, TAO2;
CC         IsoId=Q9UL54-1; Sequence=Displayed;
CC       Name=2; Synonyms=PSK1-beta;
CC         IsoId=Q9UL54-2; Sequence=VSP_015969, VSP_015970;
CC         Note=Contains a phosphoserine at position 1031 (By similarity).
CC         Contains a phosphoserine at position 1011.
CC         {ECO:0000244|PubMed:19369195, ECO:0000250};
CC       Name=3;
CC         IsoId=Q9UL54-3; Sequence=VSP_015967, VSP_015968;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=Q9UL54-4; Sequence=VSP_044894;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed, with a higher level of
CC       expression in testis and brain. {ECO:0000269|PubMed:10660600,
CC       ECO:0000269|PubMed:13679851}.
CC   -!- PTM: Isoforms 1 and 2 are autophosphorylated.
CC   -!- PTM: C-terminal cleavage of isoform 1 and subsequent nuclear
CC       localization requires CASP9 activity.
CC   -!- PTM: Autophosphorylated. Phosphorylated by ATM.
CC   -!- PTM: Isoform 2: Phosphorylated on Ser-1031 by MAPK14. This
CC       phosphorylation is required PCDH8 for endocytosis (By similarity).
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAQ89301.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAA74904.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF061943; AAD45616.1; -; mRNA.
DR   EMBL; AF263313; AAG38503.1; -; mRNA.
DR   EMBL; AB020688; BAA74904.2; ALT_INIT; mRNA.
DR   EMBL; AK291473; BAF84162.1; -; mRNA.
DR   EMBL; AL137701; CAB70882.1; -; mRNA.
DR   EMBL; AC093512; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471238; EAW79963.1; -; Genomic_DNA.
DR   EMBL; CH471238; EAW79964.1; -; Genomic_DNA.
DR   EMBL; BC136653; AAI36654.1; -; mRNA.
DR   EMBL; BC136655; AAI36656.1; -; mRNA.
DR   EMBL; BC142663; AAI42664.1; -; mRNA.
DR   EMBL; BC144344; AAI44345.1; -; mRNA.
DR   EMBL; BC151221; AAI51222.1; -; mRNA.
DR   EMBL; BC152413; AAI52414.1; -; mRNA.
DR   EMBL; AY358942; AAQ89301.1; ALT_INIT; mRNA.
DR   CCDS; CCDS10662.1; -. [Q9UL54-2]
DR   CCDS; CCDS10663.1; -. [Q9UL54-1]
DR   CCDS; CCDS58448.1; -. [Q9UL54-4]
DR   PIR; T46444; T46444.
DR   RefSeq; NP_001238972.1; NM_001252043.1. [Q9UL54-4]
DR   RefSeq; NP_004774.1; NM_004783.3. [Q9UL54-2]
DR   RefSeq; NP_057235.2; NM_016151.3. [Q9UL54-1]
DR   UniGene; Hs.291623; -.
DR   ProteinModelPortal; Q9UL54; -.
DR   SMR; Q9UL54; -.
DR   BioGrid; 114750; 17.
DR   IntAct; Q9UL54; 9.
DR   STRING; 9606.ENSP00000310094; -.
DR   BindingDB; Q9UL54; -.
DR   ChEMBL; CHEMBL1075195; -.
DR   DrugBank; DB04522; Phosphonoserine.
DR   GuidetoPHARMACOLOGY; 2234; -.
DR   iPTMnet; Q9UL54; -.
DR   PhosphoSitePlus; Q9UL54; -.
DR   BioMuta; TAOK2; -.
DR   DMDM; 116242813; -.
DR   EPD; Q9UL54; -.
DR   PaxDb; Q9UL54; -.
DR   PeptideAtlas; Q9UL54; -.
DR   PRIDE; Q9UL54; -.
DR   Ensembl; ENST00000279394; ENSP00000279394; ENSG00000149930. [Q9UL54-2]
DR   Ensembl; ENST00000308893; ENSP00000310094; ENSG00000149930. [Q9UL54-1]
DR   Ensembl; ENST00000416441; ENSP00000393048; ENSG00000149930. [Q9UL54-3]
DR   Ensembl; ENST00000543033; ENSP00000440336; ENSG00000149930. [Q9UL54-4]
DR   GeneID; 9344; -.
DR   KEGG; hsa:9344; -.
DR   UCSC; uc002dva.3; human. [Q9UL54-1]
DR   CTD; 9344; -.
DR   DisGeNET; 9344; -.
DR   GeneCards; TAOK2; -.
DR   HGNC; HGNC:16835; TAOK2.
DR   HPA; HPA010650; -.
DR   MIM; 613199; gene.
DR   neXtProt; NX_Q9UL54; -.
DR   OpenTargets; ENSG00000149930; -.
DR   PharmGKB; PA134907964; -.
DR   eggNOG; KOG0577; Eukaryota.
DR   eggNOG; ENOG410Y259; LUCA.
DR   GeneTree; ENSGT00810000125351; -.
DR   HOGENOM; HOG000236358; -.
DR   HOVERGEN; HBG094024; -.
DR   InParanoid; Q9UL54; -.
DR   KO; K04429; -.
DR   OMA; LNHRFLC; -.
DR   OrthoDB; EOG091G01CN; -.
DR   PhylomeDB; Q9UL54; -.
DR   TreeFam; TF351444; -.
DR   SignaLink; Q9UL54; -.
DR   SIGNOR; Q9UL54; -.
DR   GeneWiki; TAOK2; -.
DR   GenomeRNAi; 9344; -.
DR   PRO; PR:Q9UL54; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000149930; -.
DR   CleanEx; HS_TAOK2; -.
DR   Genevisible; Q9UL54; HS.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:UniProtKB.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0030425; C:dendrite; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0031434; F:mitogen-activated protein kinase kinase binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0030036; P:actin cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; NAS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; NAS:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0048041; P:focal adhesion assembly; IDA:UniProtKB.
DR   GO; GO:0031572; P:G2 DNA damage checkpoint; IMP:UniProtKB.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0006612; P:protein targeting to membrane; NAS:UniProtKB.
DR   GO; GO:0001558; P:regulation of cell growth; NAS:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IDA:UniProtKB.
DR   GO; GO:0006950; P:response to stress; IDA:UniProtKB.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; IDA:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell projection; Coiled coil;
KW   Complete proteome; Cytoplasm; Cytoplasmic vesicle; Cytoskeleton;
KW   Kinase; Magnesium; Membrane; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN         1   1235       Serine/threonine-protein kinase TAO2.
FT                                /FTId=PRO_0000086733.
FT   TRANSMEM    965    985       Helical. {ECO:0000255}.
FT   TRANSMEM    987   1007       Helical. {ECO:0000255}.
FT   TRANSMEM   1012   1032       Helical. {ECO:0000255}.
FT   TRANSMEM   1043   1063       Helical. {ECO:0000255}.
FT   TRANSMEM   1166   1186       Helical. {ECO:0000255}.
FT   DOMAIN       28    281       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      34     42       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COILED      486    547       {ECO:0000255}.
FT   COILED      574    601       {ECO:0000255}.
FT   COILED      681    713       {ECO:0000255}.
FT   COMPBIAS    330    336       Poly-Glu.
FT   COMPBIAS    347    370       Ser-rich.
FT   COMPBIAS    378    406       Glu-rich.
FT   COMPBIAS    791    907       Glu-rich.
FT   COMPBIAS    943   1060       Leu-rich.
FT   ACT_SITE    151    151       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      57     57       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       9      9       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     181    181       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:17158878}.
FT   MOD_RES     414    414       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     656    656       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q6ZQ29}.
FT   MOD_RES     777    777       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     825    825       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     827    827       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1    173       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_015967.
FT   VAR_SEQ     174    218       SIMAPANSFVGTPYWMAPEVILAMDEGQYDGKVDVWSLGIT
FT                                CIEL -> MMGTSQGHVARKSRNWGLNPSRLSSIPLSSTPC
FT                                HLSPSSLSPFSV (in isoform 3).
FT                                {ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_015968.
FT   VAR_SEQ     745   1049       VRAGQRPPGLPLPIPGALGPPNTGTPIEQQPCSPGQEAVLD
FT                                QRMLGEEEEAVGERRILGKEGATLEPKQQRILGEESGAPSP
FT                                SPQKHGSLVDEEVWGLPEEIEELRVPSLVPQERSIVGQEEA
FT                                GTWSLWGKEDESLLDEEFELGWVQGPALTPVPEEEEEEEEG
FT                                APIGTPRDPGDGCPSPDIPPEPPPTHLRPCPASQLPGLLSH
FT                                GLLAGLSFAVGSSSGLLPLLLLLLLPLLAAQGGGGLQAALL
FT                                ALEVGLVGLGASYLLLCTALHLPSSLFLLLAQGTALGAVLG
FT                                LSWRRGLMGVPLGLGAAW -> SKELQIKKQFQETCKIQTR
FT                                QYKALRAHLLETTPKAQHKSLLKRLKEEQTRKLAILAEQYD
FT                                QSISEMLSSQALRLDETQEAEFQALRQQLQQELELLNAYQS
FT                                KIKIRTESQHERELRELEQRVALRRALLEQRVEEELLALQT
FT                                GRSERIRSLLERQAREIEAFDAESMRLGFSSMALGGIPAEA
FT                                AAQGYPAPPPAPAWPSRPVPRSGAHWSHGPPPPGMPPPAWR
FT                                QPSLLAPPGPPNWLGPPTQSGTPRGGALLLLRNSPQPLRRA
FT                                ASGGSGSENVGPPAAAVPGPLSRSTSVASHILNGSSHFYS
FT                                (in isoform 2).
FT                                {ECO:0000303|PubMed:10048485,
FT                                ECO:0000303|PubMed:13679851,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_015969.
FT   VAR_SEQ     745    857       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_044894.
FT   VAR_SEQ    1050   1235       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10048485,
FT                                ECO:0000303|PubMed:13679851,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_015970.
FT   MUTAGEN      57     57       K->A: Loss of kinase activity. In isoform
FT                                1, excluded from the nucleus. No effect
FT                                on microtubule-binding.
FT                                {ECO:0000269|PubMed:10660600,
FT                                ECO:0000269|PubMed:12639963,
FT                                ECO:0000269|PubMed:16893890,
FT                                ECO:0000269|PubMed:17158878}.
FT   MUTAGEN     169    169       D->A: Loss of kinase activity; No effect
FT                                on MAP3K7-mediated activation of NF-
FT                                kappa-B. {ECO:0000269|PubMed:16893890}.
FT   MUTAGEN     919    919       D->N: No effect on kinase activity, nor
FT                                on JNK activation, but severe reduction
FT                                in nuclear localization and apoptotic
FT                                membrane blebbing.
FT                                {ECO:0000269|PubMed:17158878}.
FT   CONFLICT    189    189       M -> T (in Ref. 7; AAI51222/AAI42664).
FT                                {ECO:0000305}.
FT   CONFLICT   1211   1211       R -> H (in Ref. 1; AAD45616).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1235 AA;  138251 MW;  211852E690934307 CRC64;
     MPAGGRAGSL KDPDVAELFF KDDPEKLFSD LREIGHGSFG AVYFARDVRN SEVVAIKKMS
     YSGKQSNEKW QDIIKEVRFL QKLRHPNTIQ YRGCYLREHT AWLVMEYCLG SASDLLEVHK
     KPLQEVEIAA VTHGALQGLA YLHSHNMIHR DVKAGNILLS EPGLVKLGDF GSASIMAPAN
     SFVGTPYWMA PEVILAMDEG QYDGKVDVWS LGITCIELAE RKPPLFNMNA MSALYHIAQN
     ESPVLQSGHW SEYFRNFVDS CLQKIPQDRP TSEVLLKHRF VLRERPPTVI MDLIQRTKDA
     VRELDNLQYR KMKKILFQEA PNGPGAEAPE EEEEAEPYMH RAGTLTSLES SHSVPSMSIS
     ASSQSSSVNS LADASDNEEE EEEEEEEEEE EEGPEAREMA MMQEGEHTVT SHSSIIHRLP
     GSDNLYDDPY QPEITPSPLQ PPAAPAPTST TSSARRRAYC RNRDHFATIR TASLVSRQIQ
     EHEQDSALRE QLSGYKRMRR QHQKQLLALE SRLRGEREEH SARLQRELEA QRAGFGAEAE
     KLARRHQAIG EKEARAAQAE ERKFQQHILG QQKKELAALL EAQKRTYKLR KEQLKEELQE
     NPSTPKREKA EWLLRQKEQL QQCQAEEEAG LLRRQRQYFE LQCRQYKRKM LLARHSLDQD
     LLREDLNKKQ TQKDLECALL LRQHEATREL ELRQLQAVQR TRAELTRLQH QTELGNQLEY
     NKRREQELRQ KHAAQVRQQP KSLKVRAGQR PPGLPLPIPG ALGPPNTGTP IEQQPCSPGQ
     EAVLDQRMLG EEEEAVGERR ILGKEGATLE PKQQRILGEE SGAPSPSPQK HGSLVDEEVW
     GLPEEIEELR VPSLVPQERS IVGQEEAGTW SLWGKEDESL LDEEFELGWV QGPALTPVPE
     EEEEEEEGAP IGTPRDPGDG CPSPDIPPEP PPTHLRPCPA SQLPGLLSHG LLAGLSFAVG
     SSSGLLPLLL LLLLPLLAAQ GGGGLQAALL ALEVGLVGLG ASYLLLCTAL HLPSSLFLLL
     AQGTALGAVL GLSWRRGLMG VPLGLGAAWL LAWPGLALPL VAMAAGGRWV RQQGPRVRRG
     ISRLWLRVLL RLSPMAFRAL QGCGAVGDRG LFALYPKTNK DGFRSRLPVP GPRRRNPRTT
     QHPLALLARV WVLCKGWNWR LARASQGLAS HLPPWAIHTL ASWGLLRGER PTRIPRLLPR
     SQRQLGPPAS RQPLPGTLAG RRSRTRQSRA LPPWR
//
